Characterization of monoclonal antibodies against foot-and-mouth disease virus serotype O and application in identification of antigenic variation in relation to vaccine strain selection

Virology Journal

Zhidong Zhang¹  Melissa Goolia¹  Wanhong Xu¹  Ming Yang¹ 

[1] National Centre for Foreign Animal Disease, 1015 Arlington Street, Winnipeg R3E 3 M4, Manitoba, Canada

关键词: Vaccine matching;    Antigenic site;    Monoclonal antibody;    Foot-and-mouth disease;   

Others  :  1148766
DOI  :  10.1186/1743-422X-11-136

 received in 2014-03-26, accepted in 2014-07-16,  发布年份 2014

【 摘 要 】

Background

Foot-and-mouth disease (FMD) has severe implications for animal farming which leads to considerable financial losses because of its rapid spread, high morbidity and loss of productivity. For these reasons, the use of vaccine is often favoured to prevent and control FMD. Selection of the proper vaccine is extremely difficult because of the antigenic variation within FMDV serotypes. The aim of the current study was to produce a panel of mAbs and use it for the characterization of new isolates of FMDV serotype O.

Results

A panel of FMDV/O specific mAb was produced. The generated mAbs were then characterized using the peptide array and mAb resistant mutant selection. Seven out of the nine mAbs reacted with five known antigenic sites, thus the other two mAbs against non-neutralizing sites were identified. The mAbs were then evaluated by antigenic ELISA for the detection of forty-six FMDV serotype O isolates representing seven of ten known topotypes. Isolates ECU/4/10 and HKN/2/11 demonstrated the highest antigenic variation compared to the others. Furthermore, the panel of mAbs was used in vaccine matching by antigenic profiling ELISA with O1/Manisa as the reference strain. However, there was no correlation between vaccine matching by antigenic ELISA and the gold standard method, virus neutralisation test (VNT), for the forty-six FMDV/O isolates. Nine isolates had particularly poor correlation with the reference vaccine strain as revealed by the low r₁ values in VNT. The amino acid sequences of the outer capsid proteins for these nine isolates were analyzed and compared with the vaccine strain O1/Manisa. The isolate ECU/4/10 displayed three unique amino acid substitutions around the antigenic sites 1, 3 and 4.

Conclusions

The panel of mAbs is useful to monitor the emergence of antigenically different strains and determination of relevant antigenic site differences. However, for vaccine matching VNT remains the preferred method but a combination of VNT, antigenic profiling with a panel of mAbs and genetic sequencing would probably be more ideal for full characterization of any new outbreak isolates as well as for selection of vaccine strains from FMDV antigen banks.

【 授权许可】

   
2014 Yang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Kahn S, Geale DW, Kitching PR, Bouffard A, Allard DG, Duncan JR: Vaccination against foot-and-mouth disease: the implications for Canada. Can Vet J 2002, 43(5):349-354.
• [2]Hutber AM, Kitching RP, Fishwick JC, Bires J: Foot-and-mouth disease: the question of implementing vaccinal control during an epidemic. Vet J 2011, 188(1):18-23.
• [3]Barnett PV: Foot-and-mouth disease–the vaccine. Biologist (London) 2001, 48(2):55.
• [4]Paton DJ, Valarcher JF, Bergmann I, Matlho OG, Zakharov VM, Palma EL, Thomson GR: Selection of foot and mouth disease vaccine strains–a review. Rev Sci Tech 2005, 24(3):981-993.
• [5]Ahl R, Haas B, Lorenz RJ, Wittmann G: Alternative potency test of FMD vaccines and results of comparative antibody assays in different cell systems and ELISA. In Report of the Session of the Research Group of the Standing Technical Committee of the European Commission for the Control of Foot-and-Mouth Disease. Lindholm, Denmark, 25–29 June. Rome: Food and Agriculture Organisation (FAO); 1990:51-60.
• [6]Rweyemamu MM, Booth JC, Head M, Pay TW: Microneutralization tests for serological typing and subtyping of foot-and-mouth disease virus strains. J Hyg (Lond) 1978, 81(1):107-123.
• [7]Kitching RP, Rendle R, Ferris NP: Rapid correlation between field isolates and vaccine strains of foot-and-mouth disease virus. Vaccine 1988, 6(5):403-408.
• [8]World Organisation for Animal Health: Foot and mouth disease. In Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. Volume 2. 7th edition. Paris: Office international des épizooties; 2012:145-173.
• [9]Mattion N, Goris N, Willems T, Robiolo B, Maradei E, Beascoechea CP, Perez A, Smitsaart E, Fondevila N, Palma E, De Clercq K, La Torre J: Some guidelines for determining foot-and-mouth disease vaccine strain matching by serology. Vaccine 2009, 27(5):741-747.
• [10]Mattion N, Konig G, Seki C, Smitsaart E, Maradei E, Robiolo B, Duffy S, Leon E, Piccone M, Sadir A, Bottini R, Cosentino B, Falczuk A, Maresca R, Periolo O, Bellinzoni R, Espinoza A, Torre JL, Palma EL: Reintroduction of foot-and-mouth disease in Argentina: characterisation of the isolates and development of tools for the control and eradication of the disease. Vaccine 2004, 22(31–32):4149-4162.
• [11]Crowther JR, Farias S, Carpenter WC, Samuel AR: Identification of a fifth neutralizable site on type O foot-and-mouth disease virus following characterization of single and quintuple monoclonal antibody escape mutants. J Gen Virol 1993, 74 (Pt 8)(Pt 8):1547-1553.
• [12]Crowther JR, Reckziegel PO, Prado JA: Quantification of whole virus particles (146S) of foot-and-mouth disease virus in the presence of virus subunits (12S), using monoclonal antibodies in a sandwich ELISA. Vaccine 1995, 13(12):1064-1075.
• [13]McCullough KC, Crowther JR, Carpenter WC, Brocchi E, Capucci L, De Simone F, Xie Q, McCahon D: Epitopes on foot-and-mouth disease virus particles. I. Topology. Virology 1987, 157(2):516-525.
• [14]Van Maanen C, Terpstra C: Quantification of intact 146S foot-and-mouth disease antigen for vaccine production by a double antibody sandwich ELISA using monoclonal antibodies. Biologicals 1990, 18(4):315-319.
• [15]Samuel AR, Knowles NJ, Samuel GD, Crowther JR: Evaluation of a trapping ELISA for the differentiation of foot-and-mouth disease virus strains using monoclonal antibodies. Biologicals 1991, 19(4):299-310.
• [16]Seki C, Robiolo B, Periolo O, Iglesias M, D’Antuono A, Maradei E, Barros V, La Torre J, Mattion N: Rapid methodology for antigenic profiling of FMDV field strains and for the control of identity, purity and viral integrity in commercial virus vaccines using monoclonal antibodies. Vet Microbiol 2009, 133(3):239-251.
• [17]Mahapatra M, Aggarwal N, Cox S, Statham RJ, Knowles NJ, Barnett PV, Paton DJ: Evaluation of a monoclonal antibody-based approach for the selection of foot-and-mouth disease (FMD) vaccine strains. Vet Microbiol 2008, 126(1–3):40-50.
• [18]Yang M, Clavijo A, Suarez-Banmann R, Avalo R: Production and characterization of two serotype independent monoclonal antibodies against foot-and-mouth disease virus. Vet Immunol Immunopathol 2007, 115(1–2):126-134.
• [19]Kitson JD, McCahon D, Belsham GJ: Sequence analysis of monoclonal antibody resistant mutants of type O foot and mouth disease virus: evidence for the involvement of the three surface exposed capsid proteins in four antigenic sites. Virology 1990, 179(1):26-34.
• [20]Aggarwal N, Barnett PV: Antigenic sites of foot-and-mouth disease virus (FMDV): an analysis of the specificities of anti-FMDV antibodies after vaccination of naturally susceptible host species. J Gen Virol 2002, 83(Pt 4):775-782.
• [21]Rudreshappa AG, Sanyal A, Mohapatra JK, Subramaniam S, De A, Das B, Singanallur NB, Jangam AK, Muthukrishnan M, Villuppanoor SA, Pattnaik B: Emergence of antigenic variants with in serotype A foot and mouth disease virus in India and evaluation of a new vaccine candidate panel. Vet Microbiol 2012, 158(3–4):405-409.
• [22]Rweyemamu MM: Antigenic variation in foot-and-mouth disease: studies based on the virus neutralization reaction. J Biol Stand 1984, 12(3):323-337.
• [23]Pattnaik B, Subramaniam S, Sanyal A, Mohapatra JK, Dash BB, Ranjan R, Rout M: Foot-and-mouth disease: global status and future road map for control and prevention in India. Agric Res 2012, 1(2):132-147.
• [24]Yang M, Berhane Y, Salo T, Li M, Hole K, Clavijo A: Development and application of monoclonal antibodies against avian influenza virus nucleoprotein. J Virol Methods 2008, 147(2):265-274.
• [25]Briand JP, Barin C, Van Regenmortel MH, Muller S: Application and limitations of the multiple antigen peptide (MAP) system in the production and evaluation of anti-peptide and anti-protein antibodies. J Immunol Methods 1992, 156(2):255-265.
• [26]Barnett PV, Ouldridge EJ, Rowlands DJ, Brown F, Parry NR: Neutralizing epitopes of type O foot-and-mouth disease virus. I. identification and characterization of three functionally independent, conformational sites. J Gen Virol 1989, 70 ( Pt 6)(Pt 6):1483-1491.
• [27]Barnett PV, Samuel AR, Pullen L, Ansell D, Butcher RN, Parkhouse RM: Monoclonal antibodies, against O1 serotype foot-and-mouth disease virus, from a natural bovine host, recognize similar antigenic features to those defined by the mouse. J Gen Virol 1998, 79 ( Pt 7)(Pt 7):1687-1697.
• [28]Maradei E, Perez Beascoechea C, Malirat V, Salgado G, Seki C, Pedemonte A, Bonastre P, D’Aloia R, La Torre JL, Mattion N, Rodriguez Toledo J, Bergmann IE: Characterization of foot-and-mouth disease virus from outbreaks in Ecuador during 2009-2010 and cross-protection studies with the vaccine strain in use in the region. Vaccine 2011, 29(46):8230-8240.
• [29]Crowther JR: The use of monoclonal antibodies in the molecular typing of animal viruses. Rev Sci Tech 1993, 12(2):369-383.
• [30]Xie QC, McCahon D, Crowther JR, Belsham GJ, McCullough KC: Neutralization of foot-and-mouth disease virus can be mediated through any of at least three separate antigenic sites. J Gen Virol 1987, 68 ( Pt 6)(Pt 6):1637-1647.
• [31]Jackson T, Mould AP, Sheppard D, King AM: Integrin alphavbeta1 is a receptor for foot-and-mouth disease virus. J Virol 2002, 76(3):935-941.
• [32]Fox G, Parry NR, Barnett PV, McGinn B, Rowlands DJ, Brown F: The cell attachment site on foot-and-mouth disease virus includes the amino acid sequence RGD (arginine-glycine-aspartic acid). J Gen Virol 1989, 70 ( Pt 3)(Pt 3):625-637.
• [33]Nagendrakumar SB, Srinivasan VA, Madhanmohan M, Yuvaraj S, Parida S, Di Nardo A, Horsington J, Paton DJ: Evaluation of cross-protection between O1 Manisa and O1 Campos in cattle vaccinated with foot-and-mouth disease virus vaccine incorporating different payloads of inactivated O1 Manisa antigen. Vaccine 2011, 29(10):1906-1912.
• [34]Robiolo B, La Torre J, Maradei E, Beascoechea CP, Perez A, Seki C, Smitsaart E, Fondevila N, Palma E, Goris N, De Clercq K, Mattion N: Confidence in indirect assessment of foot-and-mouth disease vaccine potency and vaccine matching carried out by liquid phase ELISA and virus neutralization tests. Vaccine 2010, 28(38):6235-6241.
• [35]McCullough KC, Crowther JR, Butcher RN, Carpenter WC, Brocchi E, Capucci L, De Simone F: Immune protection against foot-and-mouth disease virus studied using virus-neutralizing and non-neutralizing concentrations of monoclonal antibodies. Immunology 1986, 58(3):421-428.
• [36]McCullough KC, Bruckner L, Schaffner R, Fraefel W, Muller HK, Kihm U: Relationship between the anti-FMD virus antibody reaction as measured by different assays, and protection in vivo against challenge infection. Vet Microbiol 1992, 30(2–3):99-112.
• [37]McCullough KC, De Simone F, Brocchi E, Capucci L, Crowther JR, Kihm U: Protective immune response against foot-and-mouth disease. J Virol 1992, 66(4):1835-1840.
• [38]Thomas A, Woortmeijer R, Barteling S, Meloen R: Evidence for more than one important, neutralizing site on foot-and-mouth disease virus. Arch Virol 1988, 99(3–4):237-242.
• [39]Mateu MG: Antibody recognition of picornaviruses and escape from neutralization: a structural view. Virus Res 1995, 38(1):1-24.
• [40]Mahapatra M, Hamblin P, Paton DJ: Foot-and-mouth disease virus epitope dominance in the antibody response of vaccinated animals. J Gen Virol 2012, 93(Pt 3):488-493.
• [41]Dunn CS, Samuel AR, Pullen LA, Anderson J: The biological relevance of virus neutralisation sites for virulence and vaccine protection in the guinea pig model of foot-and-mouth disease. Virology 1998, 247(1):51-61.
• [42]Das B, Sanyal A, Subramaniam S, Mohapatra JK, Pattnaik B: Field outbreak strains of serotype O foot-and-mouth disease virus from India with a deletion in the immunodominant betaG-betaH loop of the VP1 protein. Arch Virol 2012, 157(10):1967-1970.
• [43]Rojas ER, Carrillo E, Schiappacassi M, Campos R: Modification of foot-and-mouth disease virus O1 Caseros after serial passages in the presence of antiviral polyclonal sera. J Virol 1992, 66(6):3368-3372.
• [44]Feigelstock D, Mateu MG, Piccone ME, De Simone F, Brocchi E, Domingo E, Palma EL: Extensive antigenic diversification of foot-and-mouth disease virus by amino acid substitutions outside the major antigenic site. J Gen Virol 1992, 73 ( Pt 12)(Pt 12):3307-3311.
• [45]Altshuler E, Serebryanaya D, Katrukha A: Generation of recombinant antibodies and means for increasing their affinity. Biochemistry (Moscow) 2010, 75(13):1584-1605.
• [46]Dinka SK, Swaney LM, Vicar JW: Selection of a stable clone of the MVPK-1 fetal porcine kidney cell for assays of foot-and-month disease virus. Can J Microbiol 1977, 23(3):295-299.
• [47]Hohlich BJ, Wiesmuller KH, Schlapp T, Haas B, Pfaff E, Saalmuller A: Identification of foot-and-mouth disease virus-specific linear B-cell epitopes to differentiate between infected and vaccinated cattle. J Virol 2003, 77(16):8633-8639.
• [48]Yang M, Clavijo A, Li M, Hole K, Holland H, Wang H, Deng MY: Identification of a major antibody binding epitope in the non-structural protein 3D of foot-and-mouth disease virus in cattle and the development of a monoclonal antibody with diagnostic applications. J Immunol Methods 2007, 321(1–2):174-181.
• [49]Booth JC, Rweyemamu MM, Pay TW: Dose-response relationships in a microneutralization test for foot-and-mouth disease viruses. J Hyg (Lond) 1978, 80(1):31-42.
• [50]Martinez HM: An efficient method for finding repeats in molecular sequences. Nucleic Acids Res 1983, 11(13):4629-4634.
• [51]Lipman DJ, Pearson WR: Rapid and sensitive protein similarity searches. Science 1985, 227(4693):1435-1441.
• [52]Logan D, Abu-Ghazaleh R, Blakemore W, Curry S, Jackson T, King A, Lea S, Lewis R, Newman J, Parry N: Structure of a major immunogenic site on foot-and-mouth disease virus. Nature 1993, 362(6420):566-568.
• [53]Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE: UCSF Chimera–a visualization system for exploratory research and analysis. J Comput Chem 2004, 25(13):1605-1612.